Britain’s AstraZeneca said on Thursday that good data was coming in so far on its vaccine for Covid-19, already in large-scale human trials and widely seen as the front-runner in the race for a shot against the novel coronavirus. We have had good data so far. We need to show the efficacy in the clinical programme, but so far, so good,” Chief Executive Pascal Soriot said on a media call. Newer drugs for diabetes, heart conditions and cancer, including its top selling lung cancer drug Tagrisso, performed well in the quarter and AstraZeneca remains on track for a third consecutive year of growth. Among drugs with better-than-expected revenues, sales of respiratory drug Symbicort rose 12% to $653 million, about $90 million above consensus, while revenue from cancer drug Lynparza jumped 62% to $554 million.

Source: Standard Digital July 30, 2020 11:48 UTC